Alexander Burges

TL;DR: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.

TL;DR: Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.

TL;DR: Only complete resection was associated with prolonged survival in recurrent ovarian cancer and the identified criteria panel will be verified in a prospective trial evaluating whether it will render a useful tool for selecting the right patients for cytoreductive surgery in recurrent Ovarian cancer.

TL;DR: Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.

TL;DR: It is suggested that catumaxomab is a promising treatment option in ovarian cancer patients with malignant ascites because it prevented the accumulation of ascites and efficiently eliminated tumor cells with an acceptable safety profile.